Commercial teams can no longer afford to be operating separately from R&D – silos between the two operations will start to break down.
Drug repurposing could help find cures for rare diseases faster, but trawling through research is a time-consuming and resource-heavy task.
Real world evidence is used for post approval regulation and labeling purposes. But RWE has many more untapped uses that firms now appear keen to explore.
Social listening can be a valuable tool for pharma companies and provide a rich data stream for PV, if properly managed.
CCC is heading to Rancho Mirage from March 19-21 to attend DIA’s Medical Affairs and Scientific Communications Forum (MASC 2018).
Amazon will see you now? The lack of detail on the new partnership has opened the door for people to theorize what the healthcare initiative might involve.
The world’s biggest drug companies are finding it increasingly difficult to recoup their investments in R&D. What can be done?